Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2025)

Crinetics Pharmaceuticals has reported Total Liabilities over the past 9 years, most recently at $134.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $134.2 million for Q4 2025, up 22.21% from a year ago — trailing twelve months through Dec 2025 was $134.2 million (up 22.21% YoY), and the annual figure for FY2025 was $134.2 million, up 22.21%.
  • Total Liabilities for Q4 2025 was $134.2 million at Crinetics Pharmaceuticals, up from $123.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for CRNX hit a ceiling of $134.2 million in Q4 2025 and a floor of $14.1 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $66.5 million (2023), compared with a mean of $68.4 million.
  • Biggest five-year swings in Total Liabilities: dropped 8.91% in 2021 and later skyrocketed 206.48% in 2024.
  • Crinetics Pharmaceuticals' Total Liabilities stood at $19.1 million in 2021, then skyrocketed by 87.97% to $35.8 million in 2022, then skyrocketed by 168.49% to $96.2 million in 2023, then increased by 14.07% to $109.8 million in 2024, then rose by 22.21% to $134.2 million in 2025.
  • The last three reported values for Total Liabilities were $134.2 million (Q4 2025), $123.9 million (Q3 2025), and $118.0 million (Q2 2025) per Business Quant data.